Promethera Appoints Dr John Tchelingerian as the New Chairman of the Board
News Dec 30, 2014
Promethera Biosciences has announced that Dr John Tchelingerian has joined the company as chairman of the board. He will support Promethera to catalyze transformative transactions in the future.
Dr John Tchelingerian joins the company at a time when Promethera is gearing up to launch a pivotal phase IIb/III trial in Europe and assess new, commercially attractive indications.
Dr John Tchelingerian is a serial entrepreneur and a private investor. His background includes strong scientific, business, managerial and deal making experience. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos. In the past ten years he has raised over $100 million (€ 81 million) for his entrepreneurial ventures from VCs and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals. Under his leadership four drugs were developed from the research stage up to clinical phase IIb/III and a marketed drug, DaunoXome, was re-launched in a cancer orphan indication both in the USA and the EU, based on phase III clinical trials.
“John is a valuable addition to our energetic team in the Promethera Biosciences boardroom,” said Eric Halioua, chief executive officer at Promethera. “He will play an important role in assisting our future development plans across current and new indications of HepaStem. He has significant expertise to assist the board in its strategic decisions.”
Alain Parthoens, partner at Vesalius Biocapital and lead investor said: "We are pleased that the board will be strengthened by the arrival of Dr John Tchelingerian. He is a well known biotech entrepreneur and we anticipate that his influence will guide the company to realize its potential as a major player for unmet medical needs in liver cell therapies."
“I really look forward to working with the experienced team at Promethera,” said John Tchelingerian, PhD. “The company will continue in the development and commercialization of innovative cell therapy products based on its advanced liver stem-cell based proprietary technologies. Promethera Biosciences has outstanding potential to deliver world-class innovative therapeutic options in the treatment of liver diseases.”
John co-founded a strategic advisory and corporate finance firm Silver Ocean Ventures in 2009; based in Paris. It primarily services the global life sciences industry regarding corporate finance, strategic business transactions and active board and leadership roles. Under his leadership Silver Ocean Ventures has closed several international capital raising and M&A transactions.
As a scientist, John has invented several patents in the field of cell therapy and drug delivery. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages.
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE